HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $50 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $50 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $50 price target.